Amgen's D-mab beats Fosamax in trial

Wed, 28 May 2008 06:59:55 -0400

In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's Fosamax. D-mab, as it's known, showed greater improvement in bone mineral density in the hip and spine compared to Fosamax. "The novel means by which denosumab inhibits osteoclast-mediated bone breakdown shows the promise of RANK Ligand inhibition," said Javier San Martin, Global Development Lead for the denosumab osteoporosis program.

- see Amgen's release
- read the report for more

Biotech CEOs face rising fury of angry investors

Thu, 26 Jul 2007 06:59:56 -0400

The San Francisco Chronicle reports that a growing number of biotech execs have had to ward off the angry attacks of shareholder activists who protest the way they're running their companies. Case in point: PDL BioPharma CEO Mark McDade, who faced protests over his real estate deal for swanky new offices in Redwood City, CA. And hedge fund managers and other investors are turning up the heat on other CEOs with a questionable track record for handling money. Third Point LLC is responsible for much of this flak, mounting attacks on PDL, Ligand and Nabi. MedImmune and ImClone can both also attest to the trend.

- here's the article from the San Francisco Chronicle

Related Articles:
PDL BioPharma rises on shareholder complaint. Report
Icahn takes control of ImClone as CEO departs. Report
Nabi CEO walks after hedge fund balks. Report